Spyre Therapeutics, Inc. (SYRE) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $0.00 |
| Revenue (TTM) | $0.0B |
| Return on Equity | -18.9% |
| Operating Margin (TTM) | -27348.0% |
| Current Ratio | 18.53 |
| Revenue Growth (YoY) | -100.0% |
| FCF Growth (YoY) | 57.6% |
| Price / Book | 7.14 |
| Altman Z-Score | 66.44 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
SYRE overview · SYRE earnings · SYRE KPIs · SYRE documents · SYRE ownership · SYRE peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.